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Introduction
Approximately 5 million people suffer
from major neurocognitive disorder (MND) in
Japan, and the number is increasing.
Patients with MND prefer to remain living in
the same place where they have lived rather
than spend the rest of their life in a nursing
home. Their caregivers and medical staff,
including their familSr doctors, should provide
a way for them to comfortably spend the rest
of their life in their homes. Cardinal symptoms
Pharmacotherapy for Major Neurocognitive Disorder
University of Kagoshima Junshin Graduate School
Shin-ichi Iwata, MD
Summary
No drugs have been developed that can ameliorate major neurocognitive disorder (MND).
Some drugs can ameliorate the behavioral and psychological symptoms of dementia (BPSD),
which consists of two subtypes. The first type is positive symptoms such as hallucination and
irritation. The second type is negative symptoms such as apathy and depression. Because the
former induces serious problems for caregivers, it should be treated as soon as possible. The
latter symptoms, however, should be accepted as MND itself. Doctors generally do not
prescribe drugs for negative symptoms, as such an intervention typically ends in failure.
Caregivers manage to provide a comfortable life for patients with negative symptoms.
Anti-dementia drugs have no significant effect on MND itself or BPSD, but on the
contrary, have many adverse effects on patients with MND. Antipsychotics are effective for
positive symptoms of BPSD. Hallucination and delusion can be successfully treated with high-
potency antipsychotics. On the other hand, excitation, insomnia, and anxiety can be
ameliorated by low-potency antipsychotics. Because reaction to these drugs is variable in each
patient, and patients with MND do not explain their condition very well, precise and frequent
observation of patients is necessary.
*All disease names are adopted from DSM-5
Key words: Major Neurocognitive Disorder, Medical Therapy, Behavioral and Psychological
Symptoms of Dementia (BPSD)
of MND include memory disturbance and
executive dysfunction. Memory disturbance
induces secondary symptoms, i..e., behavioral
and psychological symptoms of dementia
(gpSO). Patients with severe aggressive
behavior may injure not only themselves but
also their caregivers. Although the cause of
aggressive behavior should be found and
treated, sedatives have to be used in an
emergency. I believe that " anti-dementia
drugs " are not necessary for patients with
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MND. I will review MND and discuss
pharmacological therapy for MND.
1. MND
1.1. Definition of MND
The category of neurocognitive disorders
(NCDs) encompasses the group of disorders
in which the primary clinical deficit is in
cognitive functior, and is acquired rather
than developmental. NCDs are those in which
impaired cognition has not been present since
birth or very early life, and thus represents
a decline from a previously attained level of
functioning. Although cognitive deficits are
present in many mental disorders, only
disorders whose core features are cognitive
are included in the NCD category. The term
" dementia" has been changed to "NCD" in the
Diagnostic and Statistical Manual of Mental
Disorders, 5th edition (pSnn-5). NCD is
classified into delirium, MND, and mild
NCD. DSM-5 diagnostic criteria for delirium
include disturbance of consciousness with
reduced ability to focus, sustain or shift
attention. An electroencephalogram is useful
to identify mild consciousness disturbance
such as delirium. When symptoms and
diagnoses are consistent with dementia, the
term "dementia" is used. The term "major"
is used when the decline in mental ability is
severe enough to interfere with the patient's
independence and daily life. MND is
diagnosed when the consciousness of a person
is clear, because delirium is sometimes
misdiagnosed as MND. Furthermore, MND
is a risk factor for delirium. In general, MND
gradually and irreversibly worselr.s. The term
"cognitive " refers to thinking and related
processes.
In DSM-5, MND is defined by a
substantial cognitive decline in one or more
of the domains listed below:
1) Complex attention, which includes sustained
attention, divided attention, selective attention,
and information processing speed
il Executive functior, which includes plannitg,
decision makirg, working memory, responding
to feedback, inhibition, and mental flexibility
3) Learnirrg and memory, which includes free
recall, cued. recall, recognition memory,
semantic and autobiographical long-term
memory, and implicit learning
4) Langunge, which includes object naming,
word finding, fluency, grammar and
syntax, and receptive language
5) Perceptual-motor function, which includes
visual perception, visuo-constructional
reasonitg, and perceptual-motor coordination
6) Social cognition, which includes recognition
of emotions, the theory of mind, and
insight
In the National Institute on Aging-
Alzheimer's Association working group criteria,
dementia is diagnosed when the patient displays
cognitive or behavioral (neuropsychiatric)
symptoms (=BPSD). In ICD 10 (1993), dementia
is defined as a chronic progressive disease
involving disturbances in higher brain
functions such as memory, cognition, and
executive functiolL.
L.2. Pharmacotherapy for MND
L.z.L. Opinions about pharmacotherapy for
MND
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No therapy for MND has been developed.
Therefore, patients with MND can only take
a medication that ameliorates clinical
symptoms. One of the cardinal symptoms of
MND is memory disturbance, but no drugs
can ameliorate this problem. Therefore,
patients with MND do not take anti-
dementia drugs with the expectation of
recovery of memory. Some medications are
effective for treating some symptoms of
BPSD, and these are justified when BPSD is
apparent and requires treatment.
Doctors and caregivers have different
opinions about the effect of anti-dementia
drugs. Some doctors prescribe anti-dementia
drugs only because they want to give
something to patients, regardless of their
actual usefulness for this purpose. On the
other hand, caregivers anticipate that anti-
dementia drugs will restore or at least
ameliorate cognitive functiorl. Caregivers
notice that these drugs do not ameliorate
cognitive symptoms but still believe these
drugs can slow exacerbation of the disease.
Anti-dementia drugs can improve memory
impairment in patients with MND by only
one point in the Mini-Mental State Examination.
Generally, the effect of anti-dementia drugs
is too weak to be noticed by their caregivers.
Therefore, anti-dementia drugs are not worth
prescribing.
Anti-dementia drugs sometimes induce
insomnia, hallucination, delusior, excitation,
and confusion, especially in patients with
MND that has progressed. These symptoms
listed above are the same as BPSD. Most
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patients with MND show BPSD during their
disease course. Therefore, discriminating the
adverse effects of anti-dementia drugs from
BPSD is confusing. Approximately 6 weeks,
which is an extended period, is needed to
wear off the effect of donep ezrl, which is
another reason that anti-dementia drugs
should not be prescribed for patients with
MND.
1.2.2. History of anti‐ denlentia drugs
The irst anti口dementia drug was the
infamous calcium hOpantenate.This drug w'as
initially adopted fOr use in deve10pmentally
delayed children with 10w lnOtivatiOn. In
1983, the drug was a1lowed to be prescribed
to patients with low motivation due to the
sequelae of cerebrovascular disease (CWアI)).
Many dOctOrs prescribed this drug nOt Only
for patients with CⅥD but also for patients
with MiND because nO drug was available fOr
patients with】旺ND.
Ⅳ[any pharmaceutical cO]m.panies deve10ped
drugs similar to calcium hOpantenate because
they were proitable.R′esearchers in these
pharmaceutical companies adopted calciuln
hopantenate as a cOntrOl in statistical studies,
because calcium hopantenate cOuld significantly
improve patients with MNI). Colmpanies did
not adopt a placebo as a control, as is typically
done,perhaps because these cOmpanies knew
that no signiicant differences 'w'ere present
in the effect Of their drugs when the placebO
was used as a control. In 1987, a new
guideline was introduced stating that a
placebo is required as a control whenever new
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drugs are evaluated. In 1996, the Ministry of
Finance demanded that the Ministry of
Health and Welfare (nntllw) require that all
anti-dementia drugs be reevaluated using a
placebo as a control. Reevaluation showed that
most anti-dementia drugs, which were called
brain metabolic stimulants or cerebral circulation
activators at that time, do not affect dementia.
Therefore, doctors did not use these drugs.
Many neurologists had previously noticed
that these drugs were useless. Many drugs
have very weak effects and are not adopted
in other countries except Japan. Many
Japanese patients take many drugs. Doctors
readily prescribe drugs to their patients, and
patients want to take drugs.
On May 19, 1998, MHLW reported that
idebenone, indeloxazine hydrochloride, bifemelane
hydrochloride, and propentofylline do not
effectively ameliorate the loss of motivation
and emotional impairment caused by C\ID.
The government alleged that improvement in
skills in a rehabilitation and nursing
environment enhances the mental condition
in patients with C\ID. That is the reason
that the four drugs mentioned above did not
show significant improvement compared with
the placebo. Such allegations are called "twi
sting the truth and truckling to the times."
The president of the Japanese medical
association responded to this report and
made a charge against the secretary of
MHLW that patients' confidence in their
doctors was severely damaged because
doctors have prescribed ineffective drugs to
patients.
I do not regard these drugs as useless,
because they may improve alertness in some
patients similar to current anti-dementia
drugs.
1.2.3. Current drugs for Alzheimer's disease
GD)
At present, no disease-modifying d.rugs
for AD are available, and thus, current
treatment aims at alleviating symptoms.
Cholinergic neurons in the basal nucleus
whose axons extend to the cerebral cortex
are severely diminished in AD. The activity
of choline acetyltransferase in this region is
decreased by 30-60yo. Augmentation of
cholinergic transmission is currently the
mainstay of treatment for AD. This
treatment is analogous to dopamine
supplement therapy in Parkinson's disease.
Acetylcholine is very rapidly broken down by
cholinesterase into choline and acetate, and
thus, cholinesterase inhibitors enhance
cholinergic transmission. The observation
that anticholinergic agents such as
trihexyphenidyl induce a state of confusion
resembling MND has given rise to the
cholinergic hypothesis that a deficiency in
acetylcholine is critical in the genesis of the
symptoms of AD. In 1993, tacrine, which was
the first cholinesterase inhibitor to affect the
brain, was approved by the United States
Food and Drug Administration, but it is
hepatotoxic and has limited use. Subsequently,
donep eztl was approved in multiple countries
in addition to Japan. The drug slightly
improves cognitive functions in patients with
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MND after 24 weeks of treatment, which is
a typical trial period in clinical studies.
However, no further improvement or some
decline was observed after 6 months. The
study showed a 6- to 12-month delay in the
progression of cognitive dysfunctions, after
which clinical deterioration resumed. Three
drugs, donep ezrl, rivastigmine, and galantamine,
are currently used as cholinesterase inhibitors
for patients with AD. Their effect is generally
weak, usually producing no dramatic
improvement in symptoms. They induce
adverse effects on the central nervous system
(CNS) such as extrapyramidal symptoms and
positive BPSD (excitation, irritation, insomnia,
delusior, hallucination, etc.), which are
difficult to distinguish from exacerbation of
BPSD. Furthermore, patients treated with
cholinesterase inhibitors tend to show
syncope , bone fractures, accidental injuries,
bradykinesia, and a higher rate of cardiac
pacemaker device insertion.
Memantine is a noncompetitive antagonist
of the NMDA-type glutamate receptor and is
used as either an adjunct or an alternative
to cholinesterase inhibitors in patients with
AD. However, co-administration of cholinesterase
inhibitors with memantine does not result in
significant improvement compared to high-
dose donep eztl adrninistration. This drug has
negative effects on the CNS, e.g., epilepsy,
positive symptoms of BPSD, vertigo, falling,
headaches, and somnolence. Doctors and
caregivers tend to misunderstand these
symptoms as a part of BPSD.
These drugs are not necessary for
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patients with MND. The first-generation
anti-dementia drugs improve apathy in some
patients, and the second-generation drugs are
also effective in restoring vitality in some
patients. However, these drugs are effective
for only a limited time. An anti-dementia
drug may sedate or induce delusion in a
certain person, but make another person
active. What will happen to each patient is
unpredictable, and thus, these drugs are not
safe for patients with MND.
L.2.4. Neurotransmitters in AD
Acetylcholine is decreased in AD. The
amount of acetylcholine is the lowest among
all neurotransmitters. Cholinergic neurons
located at the nucleus basalis of Meynert are
the central neurons affected in AD. The loss
of the nucleus basalis cholinergic neurons in
patients with AD is severe: from about
500,000 in the healthy adult to less than
100,000 in patients displaying advanced AD.
Cholinergic neuronal loss, especially in the
basal forebrain, occurs not only in AD but
also in Parkinson's disease, amyotrophic
lateral sclerosis, Down syndrome, progressive
supranuclear palsy (PSP), and
olivopontocerebellar atrophy. Loss of cholinergic
neurons and the consequent impairment in
dopaminergic transmission could be the
mechanism underlying AD-related psychiatric
symptoms.
Excessive glutamate is toxic to neurolls.
A decrease in the glutamate transporter
capacity, which increases the concentration of
glutamate in the synapse, and a selective
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loss of vesicular glutamate transporters,
which increases the concentration of
glutamate in the cytosol, have been observed
in the AD brain. Moreover, excitatory amino
acid transporter 2, which is primarily located
in perisynaptic astrocytes, is impaired in AD
and also increases the concentration of
glutamate around the synapse. Glutamate
transmission is enhanced when glycine is
bound to the GluNl subunit of the glutamate
receptor. The role of glycine in glutamate
transmission is to facilitate the recovery of
glutamate receptor sensitivity. D-serine also
binds to the GluNl subunit and enhances
glutamate transmission. However, excessive
D-serine produced in astrocytes is also
harmful to neurons. D-serine is increased in
the hippocampus of patients with AD.
Approximately 90% of hippocampal neurons
are glutamatergic. The remaining L0% of
hippocampal neurons are inhibitory, and most
are GABAergic. The hippocampal GABAergic
system is preserved in AD, meaning that
atrophy of the hippocampus in the AD brain
occurs mainly in glutamatergic neurons.
The involvement of dopamine in AD is
unclear because significant differences
between AD brain and age-matched control
brain have not been clearly shown. The
dopaminergic system gradually undergoes
several changes during the physiological
aging process. Decreased release of dopamine,
reduced dopamine receptor expression (irt
particular D2 subtypes), and reduced dopamine
transporter expression in the striatuffi, the
hippocampus, and the frontal cortex are
typical in the aged brain・  Thus, severe
degeneration of the dopaminergic system does
not occur in ノ牡:D. Lewy bodies and alpha
synucleinopathy pathology are observed in
50% of ALI) patients as well as 30% of
healthy aged controls, which means that
degeneration of dopamine neurons tends to
accOmpany AI). The degenerative alteration
Of the  dOpaFninergiC  SyStem  iS  different
between ALI) and Parkinson's disease. In
Parkinson's disease, the dorsal striatum is
predominantly affected, whereas the dorsal
striatum is relatively spared,and the nucleus
accumbens is prOfOundly affected in .ALI).
Patients with 」LI), particularly in the later
stage, show bradykinesia, gait disturbance,
face masking, and tremor.As mentioned
earlier, these extrapyraHlidal sylnptonls are
not due to the failure of the dopaHlinergic
systenl but extranigral systenls such as the
frontal cortexo The earlier the impairim.ent of
the doparninergic systenl occurs, the faster
the cOgnitive decline in healthy aging and AI).
Therefore, enhancelmtent of the dopaminergic
system may ilnprOve sOme cognitive functions
in AD.
P1lhe serOtonergic systenl is also impaired
in .AI).This impairim.ent is not inherent in
the etiology of ハLI〕 but is associated with
non‐ cognitive lBPSI)such as lnood disturbance,
ernotion  expression,  appetite,  wake‐ sleep
cycle,confusion,agitation,and depressono The
amount of se]【)tonin, serotonergic innervation
in the brain, and the nulnber of serotonergic
neurons in the raphe are reduced in the
postlnorteHl .ALI)brain●  Notwithstanding the
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denervation of serotonergic systems in the
brain, a decrease in serotonin receptors has
been reported. A reduction in 5-HT2A
receptors has been observed with positron
emission tomography (PET) in AD. A reduction
in 5-HT1A receptors in the temporal cortex is
correlated with aggressive behavior in AD,
whereas reduced binding of these receptors in
the hippocampus is correlated with cognitive
decline. PET imaging has shown a reduction
in 5-HT1A receptor binding in the hippocampus
and parahippocampus in patients with mild
AD. The density of 5-HT1B/1D and 5-HT6
receptors is reduced in the frontal and
temporal cortex in AD. 5-HTG receptors are
present in the cerebral cortex and are related
to cognitive function.
The histamine concentration in the brain
is diminished in patients with AD. The
tuberomammillary nucleus, which is the only
source of neuronal histamine in the brain,
degenerates in patients with AD.
2. BPSD
2.L. Definition and characteristic symptoms
of BPSD
The International Psychogeriatric Association
defines BPSD as symptoms of disturbed
perception, thought content, mood, or
behavior that frequently occur in patients
with MND. BPSD is classified into two types,
positive symptoms and negative symptoms.
Besides this classification, BPSD is also
categorized into psychological symptoms and
behavioral symptoms. Psychological symptoms
of BPSD are revealed by asking caregivers
and patients. They include delusior, false
recognition, hallucination, depression, apathy,
insomnia, and anxiety, Behavioral symptoms
of BPSD include poriomania, aggression,
resistance to caregivers, inappropriate sexual
behavior, emotional stress reactioh, dusk
reactioh, screamirg, restlessness, collectionisffi,
swearirg, and following. They are revealed
by observing the patient's behavior. Deliriuffi,
which is a disturbance of consciousness with
excitation, is a different concept from BPSD.
However, caregivers, in general, cannot
distinguish delirium from BPSD. The type of
BPSD symptoms depends on the
circumstances where the patient lives.
Caregivers may misunderstand the patient's
behavior as BPSD. Doctors should ask
several people caring for the patient with
MND whether the behavior that the caregiver
reports is considered BPSD or is a legitimate
claim of the patient. Almost all drugs acting
on the CNS can induce BPSD. Among non-
CNS-acting drugs, HZ blockers, anti-
histaminergic drugs, and an anticholinergic
drug can induce BPSD.
Each type of MND has specific positive
symptoms. A delusion of theft is a frequent
psychological symptoffi, and poriomania is a
frequent behavioral symptom in patients with
AD. Patients with vascular NCD show unstable
mood, irritability, and day and night reversal.
Furthermore, these specific positive symptoms
are specific to the disease stage. Delusion of
theft and blaming family members are
frequently seen in the early stage of AD. As
the disease progresses, behavioral abnormalities
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such as poriomania and resistance to caregivers
appear. Patients' anxiety causes poriomania.
They forget the purpose of leaving home
because of memory disturbance. They do not
understand where they are, which is the
typical symptom of visuospatial disturbance.
In DSM-5, hallucination is defined as a
perception-like experience with the clarity and
impact of a real event but without external
stimulation of the relevant sensory organ.
Among hallucinatiors, visual hallucination is
frequently seen in MNDi on the other hand,
auditory hallucination is dominant in
schizophrenia. Vivid visual hallucination is a
characteristic symptom in patients with NCD
with Lewy bodies. Visual hallucination is
also seen in approximately 20% of patients
with AD. In frontotemporal NCD and
vascular NCD, visual hallucination is rarely
observed.
Sexual disinhibition embarrasses the
patient's family members. The disinhibition
of instinct is due to damage to the
orbitofrontal cortex. Many subtypes of MND,
e.9., frontotemporal NCD, AD, and vascular
MND, involve sexual disinhibition.
Antipsychotics are worth trying to dampen
sexual disinhibition. When the patient is
male, intensive care by male caregivers
suppresses sexual disinhibition. Benzodiazepine
and dopamine agonists induce and exacerbate
sexual disinhibition.
In DSM-5, agitation is defined as
excessive motor activity associated with a
feeling of inner tension. The activity is
usually nonproductive and repetitious, and
consists of behaviors such as pacing,
fidgetirg, wringing of the hands, pullittg of
clothes, and the inability to sit still. Half of
patients with MND show agitation. At the
beginning of the disorder, patients are
anxious about their loss of cognitive function,
and so they are agitated. As the disease
progresses, the patients feel agitation because
of misunderstanding of their circumstances.
Caregivers should look into the person's
physical condition and whether agitation
behavior comes from physical probleffis,
which should be addressed. Antidepressants
exacerbate agitation because the drugs
induce serotonin syndrome and activation
syndrome.
Aggression is classified into violence and
ranti both are seen in the advanced stage of
MND. Patients with MND express aggression
when they are receiving care from caregivers
with little experience with the patients.
Caregivers should pay attention to patients'
suicidal tendencies because the target of
violence occasionally turns to the patients
themselves. Physical violence occurs quite
often and is a serious problem. Risk factors
for aggression are male sex, body pain,
constipation, low activities of daily living
(ADL), advanced MND, difficulty in
communication, violent character, and
nervous character. Patients with MND will
be angry when somebody prevents them from
doing what they want to do. Hypofunction of
the frontal lobe and the temporal lobe is
responsible for this irritability. A premorbid
characteristic such as lack of coordination or
-10-
frustration is related to the irritability.
The "desire to go home" phenomenon is
frequently seen in nursing homes and
happens in patients with the advanced stage
of MND. This phenomenon is also seen even
when patients are in their homes because
some patients do not think that they are
living in their own house. They go out
looking for their home. When patients think
that they are not in their homes, they think
it is time to go home in the evening. In the
evenihg, caregivers finish working and start
to go home, stimulating the patients to try to
go home. Caregivers can persuade them to
remain where they are by telling the
patients " Here is a hotel, and tonight you
are going to stay here." Dusk reaction means
exacerbation of positive symptoms of BPSD
or cognitive function. This phenomenon ofen
coexists with the " desire to go home "
phenomenon.
Interference is not a popular word
because the concept is difficult to understand.
The patient with interference perpetually
corrects others' behavior, not caring about
others' feelings. Such a patient may hide
others' cutlery during a meal, pull out all
drawers and scatter items in the room, or
pull off all the toilet paper on the roll.
Interference can be seen in someone who
once cared for someone else and persists.
When caregivers try to stop this behavior,
the person becomes frustrated and angry. To
stop such interference, caregivers may try to
distract the person and ask them to do other
activities such as folding laundry.
Pharmacotherapy for Major Neurocognitive Disorder  岩田真―一
Collectionislm.is the habit of collecting
meaningleSS itelmLS.A cause of this behavior
is loneliness.
Fecal smearing appears in.tlle late stage
of patients with 〕⊆NI)。 The cause of this
behavior is fecal incontinence and a lack of
understanding of what to do with the feces.
Patients who use an adult diaper tend to
show fecal slm.earingo Some patients enJoy the
feeling of feces。
Insomnia is widespread in patients with
MNI).A physical problem such as back pain
or gastroesoph.ageal regu.rgitation disrupts
sleepo I)isruption of the circadian rhythm is
one cause of insomnia.The best way to sleep
well is to participate in activities in the
daytiln.e  a:n.d  to  avoid  a  midday  nap.
0)versleeping in the morning can be caused
by a hangover fronl hypnoticse Short‐ acting
hypnotics should be used whenever a person
needs these lnedicationso When patients wake
up  in  the  nliddle  of the  night,  they
sometimes show night deliriunl. In such
cases,hypnotics cannot remedy insomnia with
deliriunl.In general,non“ benzodiazepines such
as zolpidem (1肛 yslee③),zopiclone(AmobanQ),
and eszopiclone(Renesta Q); and melatonin
agonists such as ramelteon(RozeremQ)are
preferable,but such weak drugs cannot induce
sleep in patients with delirium.Therefore, a
potent and short‐acting benzodiazepine such
as triazolanl is used. However, triazolaln
induces anterograde amnesia and delusion;
therefore, 0.125 1ng triazolanl is preferable to
O。25 mg. If patients cannot sleep with O.125
mg triazolanl, I add anti“ histanlinergic drugs
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such  as  hydroxyzine  and  an  atypical
antipsychotic such as quetiapineo Single use
of quetiapine is one of the best uses of this
drug as a hypnotic. R′ecently, tandospirone
was reported to be preferable for treating
insOmnia because it has few adverse effects.
0)rexin  receptor  antagonists   such  as
suvOrexant(BelsomraQ)can be used.Rapid
eye movement(REiM)sleep movement disorder
is sometimes misdiagnosed as night delirium.
RE:M sleep movement occurs缶 om midnight
to early lnorning, but night delirium occurs
in the evening.
Patients may feel anxiety and loneliness,
and thus, remaining close to caregivers is
helpful to ease their loneliness.
Apathy is deined as a decrease in volition
and interest ain.d is sometimes misdiagnosed
as depression or refu.sal to communicate with
others. Apathy is frequently accolm.panied by
缶ontotemporal NCD, vascular NCD, and
extrapyranlidal disorderso Appetite loss is
sornetilnes derived fronl apathy; therefore,
caregivers should judge whether the person
cannot eat or will not eato Patients with
apathy do not complain, but patients with
depression  colnplain  about  their  imtental
disorder,which helps to discriminate between
apathy and depression. Drugs that stimulate
the CNS should not be used in patients with
apathy, because such drugs do not work
appropriately ain.d also indu.ce adverse effects
such as positive sylm.ptoms of BPSI).Impairim.ent
of the lm.esocorticolilnbic dopaminergic systeln
has  been  consistently  reported  to  be
responsible for apathy。  ][玉ypofunction of the
frontal cortex is the principal cause of
apathy. Therefore, apathy is MND itself.
Intensive care is the best choice for these
patients. Doctors and paramedical workers
should explain the status quo of the patient
to the persoris family and explain that apathy
is a principal symptom of MI.[D and that it
should be accepted as a natural course of
MND.
Depression in patients with MND is
difficult to identify because the countenance
of patients is often a somewhat masked face.
Depression is concealed by physical
complaints that accompany depression. The
best treatment for depression is to utilize
social support such as daycare or day service.
The effect of antidepressants is equivocal,
and neither selective serotonin uptake inhibitors
(SSRIs) nor mirtazapine can improve
depression.
Eating disorders in patients are
categorized as apathy, anorexia, and food
cognitive impairment. Continuous chewing
without swallowing indicates dysphasia
because swallowing is a vulnerable function
in patients with MND. Eating meals in a
common room rather than in an individual
patient's room may encourage residents in
nursing homes to communicate with each
other. Patients with MND, however, are
distracted by other residents and cannot
concentrate on eating a meal. Tube feeding
has no advantage for life expectancy or
nutritional amelioration.
Pseudowork is meaningless work such as
pulling clothes from drawers, putting them
-12-
back, and repeating this behavior endlessly.
If the behavior is not harmful, it is better
left unaddressed.
2.2. Assessment of BPSD
To assess the condition of patients with
BPSD, both ADLs and BPSD should be
evaluated. ADLs are classified into basic
ADLs (naOl,s) and instrumental ADLs
(IADLs). IADLs are used to determine
whether the person can live by him/herself.
BADLs are assessed with the Nishimura
ADL Scale or the Barthel Index. The Lawton
IADL Scale is used to assesses IADLs.
Many scales are available to assess
BPSD. The Neuropsychiatric Inventory is the
most popular and is composed of L2
questionnaires (delusion, hallucination, agitation/
aggression, depression/dysphoria, anxiety, elation/
euphoria, apathy/indifference, disinhibition,
irritabilityflability, motor disturbance, night-
time behavior, and appetite/eating). ADLs are
assessed with the Physical Self-Maintenance
Scale, which is the most popular. Six basic
categories (toiletirg, feeding, dressitrg, groomirg,
physical ambulation, and bathing) are scored
in the Physical Self-Maintenance Scale. The
Clinical Dementia Rating is a widely utilized
clinical tool for grading the relative severity
of MND, by which caregivers evaluate memory,
orientation, judgment, problem solving,
community affairs, home and hobby, and
personal care.
2.3. Places where patients with MND should
live
The Japanese government recommends
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that patients with MND live in their homes
using general support systems (New Orange
Plan 2AL5 by the Ministry of Health, Labor
and Welfare). Because BPSD is a significant
cause of hospitaltzation, caregivers in their
homes must take care not to induce BPSD in
patients with MND. When patients with
MND show BPSD, a manual about how to
manage BPSD is an essential tool for
caregivers. Not all MND patients show
BPSD. BPSD is sometimes caused by stress
due to people around the patients, because
patients may feel anxious when they cannot
satisfy their psychological needs. Patients
may go astray and show BPSD.
Caregivers sometimes experience burnout
and may abuse their patients. Therefore,
caregivers should visit a hospital when their
nursing home patients display BPSD. Doctors
will explain to the caregivers that the
positive symptoms of BPSD of the patients
will disappear soon, and caregivers may feel
relieved.
Financial problems are associated with
coping with BPSD, according to Section 2
Long-Term Care Health Facilities (so-catled
Rohken in Japanese). The fee for a doctor's
visit and the costs of drugs in Section 2
Long-Term Care Health Facilities are not
included in Rohken. Therefore, seeing a
doctor frequently is an extra expense.
When a patient with BPSD is too violent
to cope with in his or her home, the patient
should be compulsorily hospitalized in a
psychiatric hospital in accordance with the
law of hospitaltzation for medical care and
protection.
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The guidelines of the American Psychiatric
Association state that patients with AD
should remain in a simple living situation
with no environmental changes.
2.4. Pharmacotherapy for BPSD
2.4.L. Perspective
Although non-pharmacological approaches
to the treatment of BPSD should be considered
first, they are often ineffective. Whenever
caregivers are exhausted by dealing with
BPSD, they should go to the hospital to
obtain medications prescribed by doctors.
Although a variety of pharmacological options
are available, none of them work very well.
Both cholinesterase inhibitors and glutamatergic
drugs may reduce BPSD, especially negative
symptoms. Their effects are modest, however,
and they do not successfully treat some of
the most troublesome symptoms such as
agitation. On the contrary, these drugs often
worsen positive symptoms.
Among BPSD, a sudden onset type of
BPSD may be due to physical reasons in the
patients. Patients with severe MND cannot
state their complaints properly to caregivers.
Stupor condition may be the only symptom
even when the patients have serious medical
problems. Coping with patients with BPSD is
similar to coping with severe patients in the
emergency department.
Memory disturbance is not curable, but
BPSD is curable with appropriate medical
treatment. To treat BPSD with drugs, a
precise diagnosis of MND is required,
because patients with NCD with Lewy bodies
should be prescribed antipsychotic drugs with
caution. On the other hand, drugs for BPSD
are prescribed not according to the diagnosis
but the symptoms. For example, low-potent
antipsychotics are used for agitation, and
high-potent antipsychotics are used for
hallucinatiolr.. The number of drugs should be
as few as possible. Whenever BPSD
disappears, the amount of antipsychotics is
slowly reduced and stopped.
Caregivers misunderstand that patients
with positive symptoms are active. The
opposite is true. Sedatives over-sedate these
patients. Caregivers and doctors typically pay
attention to their physical disease complications,
because patients with MND, most of which
are aged, often suffer from many other
diseases such as chronic heart failure,
diabetes, hypertension, and arteriosclerosis.
Physical, mental, and economic problems
in patients with MND are variable.
Characteristics of family members and
caregivers are variable. Doctors ask not only
patients but also their caregivers about the
chief complaint. Doctors also evaluate the
comprehensive ability of caregivers and the
ability of caregivers to nurse their patients,
Care managers and social workers are of
great help in caring for these patients and
families. An eager caregiver is sometimes
codependent on the patient. Such caregivers
do not want to sedate their patients even if
the patients show violence because they feel
that the patients are wrongfully treated
when the patient is administered a sedative.
-14-
2.4.2. Antipsychotics for BPSD
Although no drugs for BPSD are covered
by health insurance, quetiapine, haloperidol,
perospirone, and risperidone are permitted
for treatment of delusior, psychomotor
excitation, and irritabitity due to MND.
Antipsychotics are prescribed in approximately
2A% of MND patients. In general, non-
pharmacological care should be tried first for
patients with BPSD. When this does not
work, antipsychotics are administered. However,
in an emergent patient such as one in a
major depressive state or one who injures
himself/herself or others, antipsychotics should
be used first.
Because aged patients and patients with
MND are sensitive to medications, the dose
of antipsychotics should be started at one-
half or one-fourth of the regular dose. Doctors
should evaluate the effect of antipsychotics
within a week, which is a short period for
regular assessment of antipsychotics. For
example, at least 2-4 weeks are typically
required for antidepressants to begin to
work. In the guidelines for MND 20L7,
atypical antipsychotics are recommended for
treatment of anxiety, restlessness, delusior,
and hallucination. The effect of antipsychotics
on the treatment of poriomania is
controversial, but I feel that antipsychotics
are effective. The guidelines state that the
level of evidence is C (weak) and that the
grade of recommendation is 2 (weak). In
other words, atypical antipsychotics can be
used for BPSD, but it depends on the case.
Pharmacotherapy for Major Neurocognitive Disorder  岩田真一一
Antipsychotics are efficacious for positive
symptoms of BPSD, but their use is often
limited by their adverse effects, e .9.,
Parkinsonisffi, sedation, and falling. In
addition to these adverse effects, the use of
atypical antipsychotics in elderly patients is
associated with a higher risk of stroke and
overall mortality.
For agitation, atypical antipsychotics are
effective. Among antipsychotics, a low dose of
risperidone is the best, and aripiprazole has
the same effect as risperidone. The effect of
olanzapine is equivocal, and quetiapine is not
effective, Person-centered care by caregivers
is required for all care of patients with
MND. Person-centered care is focused on the
needs of the person rather than the needs of
the service judged by medical staff. Patients
have views on what is best for them and on
their priorities in life. Thus, health care
workers should meet their needs.
Benzodiazepines can be used for
occasional control of acute agitation but are
not recommended for long-term management
because of their adverse effects on cognition,
muscle weakness, and falling. Even for
anxiety and insomnia, which are generally
thought to be good indications for
benzodiazepines, antipsychotics can be used
instead of benzodiazepines in patients with
MND. Among antipsychotics, risperidone,
olanzapine, and quetiapine are recommended.
Haloperidol is not adequate for anxiety.
Typical antipsychotics such as chlorpromazine
and haloperidol may be useful for aggression,
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but extrapyramidal symptoms, especially
with haloperidol, limit their use to
controlling acute episodes. Haloperidol is not
recommended as the first-line drug for BPSD.
Antipsychotic drugs prescribed for BPSD are
not covered by health insurance. They are for
schizophrenia. However, some drugs are
permitted for use in patients with BPSD.
The Japan Consortium for Antipsychotics
Treatment in AD is a large cohort in which
the effect of antipsychotic treatment for
BPSD on mortality was studied. No
significant differences were seen between
patients who received antipsychotics and
patients who did not. However, the mortality
rate jumped up 2.5-fold when patients were
newly treated and then continued to be
treated for over 11 weeks. No particular
cause of death was noted in the patients
newly treated with antipsychotics. They died
of pneumonia or senility. Importantly, the
average age at the beginning of the study
was 81 years. Naturally, antipsychotics are
harmful to older people. Furthermore, patients
with MND who have BPSD and need
antipsychotics are sensitive to nearly all
drugs. Over-sedation, hypotension, falling,
dysphasia, edema, and malignant syndrome
are listed as adverse effects of antipsychotics.
Moreover, exacerbation of glucose intolerance
is evident in patients treated with olanzapine
and quetiapine. The longer antipsychotics are
used, the worse cognitive function becomes.
To identify an extrapyramidal adverse effect
early, wrist rigidity should be checked
because it is an easy technique to identify
Parkinsonism.
2.4.3. Anti'AD drugs for BPSD
Cholinesterase inhibitors are not useful
for positive symptoms. They exacerbate
irritability and fretfulness. Scientific evidence
for the use of anti-dementia drugs for BPSD
is not sufficient.
2.4.4. Antidepressants for BPSD
Antidepressants may be useful for
patients with hypochondria who repeatedly
complain about poor physical conditions.
Hypo-activity should be discriminated from
depression. Depressive mood and inappropriate
guilt are apparent in one-fourth of patients
with MND. Among all types of antidepressants,
SSRIs or serotonin noradrenaline reuptake
inhibitors (SNRIs) should be used first.
Tricyclic antidepressants are not suitable
because of their severe anticholinergic damage
to the CNS (".g., delirium) and peripheral
organs (..g., dry mouth, constipation, and
urinary retention). Serotonin syndrome includes
myoclonus, hyperhidrosis, and tachycardia in
addition to restlessness and irritation, Besides
these symptoms, hyperueflexia, myoclonus,
muscle rigidity, fever, diaruhea, and flushed
skin are listed as symptoms of serotonin
syndrome. SSRIs and SNRIs may induce
serotonin syndrome when these drugs are
started or added to other drugs. When
patients show such symptoms, SSRIs and
SNRIs should be stopped. When patients are
-16-
still very confused after stopping these
me dic ations, chlorp rom a zine and b enzodi azepine s
are administered to treat confusion. Anti-
dementia drugs also cause serotonin syndrome,
which may continue for more than 2-3 weeks
because anti-dementia drugs such as donep eztl
have a longer half-life in the brain than in
the blood. Trazodone may be useful for anxiety
and sexually inappropriate behavior. SSRIs
may exacerbate apathy, which is sometimes
difficult to discriminate from depression. SSRIs
also induce hyponatremia.
2.4.5。 Other drugs for BPSD
y"。kukansan can sedate irritable patients.
This effect is Πlild, sO it is useful ゴOr mild
agitationo Although this drug dOes nOt induce
any severe adverse effects on the CNS,
weakness  in  lower  extrenlities  due  tO
hypokalemia may Occur.
]Benzodiazepines are not reconlmended
because they induce over‐ sedatiOn, delusiOn,
ataxia, cognitive impairment, and falling,
especially in  patients  over  75  years  or
patients with DINI).Long‐ acting benzOdiazepines
such as ethyl lo■azepate(MeilaxQ)are wOrse
than short‐ acting Ones such as etizOlaln
(Depas o).Zolpidem (M[yslee ③ ), zOpic10ne
(Amoban③ ), and eszopiclone(Lunesta③ )are
reconllnended ihypnotics.
AInantadine is an anti‐ParkinsOn drug.
Its mechanism of actiOn is unclear but
appears  to  involve presyinaptic  dopamine
reuptake blockade, facilitation of dOpamine
release, postsynaptic dopalnine agOnisnl, and
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receptor modulation.It also has anticholinergic
properties  and  blocks  NM:DA  glutamate
receptors, which lnay induce iBPSD and
exacerbate   cognitive   functiono   When
administered in  the  morning,  this  drug
lncreases awakenlng。
Carbamazepine  is  u.sed  as  a  lnood
stabilizer for manic disorder; therefore, it is
also used to treat irritabilityo I'Iowever, it
lnduces dizzlness and drowslness even ln a
snlall dose. This drug appears to lilave no
beneit for lttND.Patients with MND are apt
to show epilepsy as the disease progresses.
Especially in nLI〕 , alm.yloid protein that has
accumulated in the hippocampus becomes a
focus of epilepsy. The dominant type Of
epilepsy in patients with ilttNI) is nonロ
convulsive. Valproic acid is the best choice
for patients with MND)because it has few'er
adverse effects on cognitive function and
because of its effectiveness on positive lBPS]D
such as irritability. New antiepileptics are
useful for epilepsy in aged patients.Among
them,  lamotrigine  (Lamictal Q) and
levetiracetam (Ekepla ① )are COVered by
health insurance and can be prescribed in
the early stage of」 生I).
3. Diseases that show MND
In DSM-5, NCD is subdivided into AD,
frontotemporal NCD, NCD with Lewy bodies,
vascular NCD, NCD due to traumatic brain
injury, substance/medication-induced NCD,
NCD due to HfV infection, NCD due to prion
disease, NCD due to Parkinson's disease,
-17-
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NCD due to Huntington's disease, NCD due
to another medical condition, NCD due to
multiple etiologies, and unspecified I.[CD.
However, clinically, MND is classified into
AD, frontotemporal NCD, NCD with Lewy
bodies, Creutzfeldt-Jacob disease, and other
neurodegenerative diseases, because each
disease has characteristic features that
require special care and attention.
3.1. AI)
AD is diagnosed when it is proven
pathologically. The Alzheimer's type of NCD
is diagnosed when clinical features are
similar to pathologically proven AD. Most
studies have been performed in clinically
diagnosed AD. Approximately 30-40 years
&go, the term " senile dementia of AD " was
only used in living patients. However,
nowadays, the word "AT) " is often used to
describe living patients.
Diagnostic criteria for AD in DSM-5
include gradually progressive MND in more
than a couple functional disabilities. In DSM-
5, neurocognitive functions are classified into
six domains: 1) complex attention, 2) executive
function and plannirg, 3) learning and memory,
4) langusge, 5) perceptual-motor functior, and
6) social cognition. Social cognition is often
preserved until the late stage of the disease.
In the early stage, depressive state and
apathy are comrnon. In the middle stage,
psychiatric symptoms are apparent. Moreover,
in the end stage, neurological symptoms such
as dysphasia, incontinence, myoclonus, and
epilepsy may be apparent. Until the 1980s,
vascular NCD was over-diagnosed. AD is,
however, over-diagnosed at present.
Patients with AD are generally gentle
and friendly to doctors. Even when they
resist their caregivers, they are gentle in
front of doctors. Caregivers should not react
emotionally against patients with AD, because
the patient's feelings are not impaired. Patients
with AD who quarrel with their caregivers at
home become very quiet and smile in front of
doctors. Doctors and caregivers understand
this symptom. Even when such patients
refuse a suggestion from their caregivers, the
doctor may be able to persuade them.
The cardinal and initial symptom of AD
is the disturbance of episodic memory. Episodic
memory is memory of autobiographical events
(times, places, associated emotions, and other
contextual knowledge related to who, what,
when, where, and *hy) that can be explicitly
stated or conjured. It is the collection of past
personal experiences that occurred at a
particular time and place. To identify
memory disturbance in patients with AD, the
delayed recall examination is the most
sensitive. Patients cannot recall when a hint
is given. Time orientation is the first
symptom among all orientation disturbances.
Then, place and person in that order.
Executive dysfunction appears relatively early
in the disease and hinders working in the
office and at home. Then, aphasia and social
cognitive dysfunction such as visuospatial
dysfunction and personality changes appear.
- 18-―
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Aphasia is initially amnesic then sensory.
Frequency and repetition are relatively
conserved. Patients who suffer from visuospatial
dysfunction may go astray even around their
house and cannot copy figures. IADLs are
impaired early in the disease, but ADLs can
be preserved.
As the disease progresses, 80% of patients
show BPSD. Depression and apathy are common
in the beginning. Irritability, confusion, refusal,
hallucination (auditory), delusion (especially
thief delusion), delirium, insomnia, and
poriomania may be apparent in the middle
stage. Myoclonus and convulsion indicate the
terminal stage of the disease.
3.2. Flontotemporal NCD
The disease concept of frontotemporal
NCD is complex. Frontotemporal NCD is a
clinical entity that is based on topography,
which is classified into a behavioral variant
of frontotemporal NCD, semantic NCD, and
progressive non-fluent aphasia. Even though
frontotemporal NCD is classified into three
types, they show the same symptoms when
they progress. Although frontotemporal lobar
degeneration is a pathological entity, the
name is adopted in the Japan Intractable
Disease Center. In DSM-5, frontotemporal
NCD is divided into two subgroups, the
behavioral type and the language disorder
type.
Frontotemporal lobar degeneration (tr'tl,D)
is classified into FTLD-tau, FTLD-TDP43
(tan DNA-binding Protein of 4BkDa), and
FTLD-FUS (fused in sarcoma) according to
characteristic proteins in abnormal inclusions.
Beside FTLD, abnormal tau also exists in
AD, PSP, and corticobasal degeneration (CBD).
Tauopathy is classified into two types: three-
repeat tauopathy and four-repeat tauopathy.
Frontotemporal NCD is classified into three-
repeat tauopathy. PSP, argyrophilic grain
disease, and CBD are classified into four-
repeat tauopathy. Both types of tau are
present in the brain of AD. An excessively
phosphorylated, ubiquitinated, and cleaved
form of TDP43 and mutation in FUS also
exist in amyotrophic lateral sclerosis. More
than 5A% of behavioral variants of
frontotemporal NCD, 80% of semantic NCD,
and 70% of progressive non-fluent aphasia
are FTLD-TDP variants.
In frontotemporal NCD, BPSD is apparent
before memory disturbance. BPSD listed in
frontotemporal NCD as diagnostic symptoms
are as follows:
1) Socially disinhibited behavior (socially
inappropriate behaviori lack of courtesy and
mannersi impulsive, indiscriminate, and
casual action)
il Indifference or apathy
3) Lack of empathy (lack of reaction to other
people's desires and feelingsi reduction or
loss of social interesti interaction with others
or human warmth)
4) Adherence/stereotypy (repetition of primitive
movements, e.9,, tapping a table repeatedlyi
compulsive ritual behavior, e.g., going to the
toilet without micturition)
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5) Oral tendency (pica) and changes in eating
habits (alteration of taste, e.g., sweets loveri
bulimiai an increase in drinking and smoking)
Among them, apathy and stereotypy are often
the first symptoms.
These symptoms are difficult to treat.
Only SSRIs are weakly recommended in the
literature. I believe antipsychotics should be
used to sedate patients with frontotemporal
NCD who show problematic symptoms. When
the disease progresses, disinhibition becomes
inconspicuorrs. Abnormal eating behavior may
be treated with Yokukansan or aripiprazole.
Cholinesterase inhibitors exacerbate these
symptoms.
3.3. NCD with Lewy bodies
The prevalence of pathologically proven
NCD with Lewy bodies is 20% of all MND.
However, the MHLW Group Research stated
that the prevalence is only 4.5oh. Cardinal
diagnostic criteria include:
1) Fluctuating impairment of cognition with
attention and arousal levels
2) Appearance of concrete delusion
3) Parkinsonism
Haunted hallucinations may be misdiagnosed
as delirium. A low dose of cholinesterase
inhibitors may be useful for not only cognitive
function but also hallucination. Clinical features
of NCD with Lewy bodies include a vivid
visual hallucination, REM sleep movement
disorder, hypotension, and excessive reactions
to drugs. Among them, visual hallucination
with anosodiaphoria should be treated with
antipsychotics. Quetiapine, olar,zaprre, and
risperidone are useful, but exacerbation of
Parkinsonism is inevitable. These medications
should be tried carefully, because patients
with NCD with Lewy bodies are sensitive to
antipsychotics, especially their sedative effect,
which prevents them from staying awake.
Furthermore, these patients are prone to
falling asleep. Their blood pressure markedly
decreases when they stand up and increases
when they lay down. All atypical
antipsychotics that have a similar structure
as chlorptomazine, e.g., euetiapine and
olanzapine, have o -blocking activity,
which induces orthostatic hypotension. All
antipsychotics more or less worsen
Parkinsonism in these patients. Among all
antipsychotics, quetiapine has a low effect on
worsening of Parkinsonism. Although haloperidol
and serotonin-dopamine antagonists such as
risperidone do not induce hypotension and
excess sedation, they induce Parkinsonism
more than chlorpramazine-like antipsychotics
and aripiprazole. As the disease progresses,
the amount of antipsychotics and
antiparkinsonian drugs should be varied. For
example, a small dose of levodopa with dopa
decarboxylase inhibitor, such as 100 mg/day,
exacerbates hallucination at the beginning of
the disease, but 600 mg/day does not induce
hallucination when the disease progresses.
Donep eztl is the only drug that is
covered by health insurance for NCD with
Lewy bodies, because the activity of
cholinergic neurons is more damaged than
-20-
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that in AD. Although a randomized
controlled trial of donep eztl suggested that
BPSD, &s well as cognitive functioh, were
significantly improved by the drug, I do not
think that donep ezil is worth prescribing,
because donep eztl is too weak to address
BPSD. Moreover, in general, antipsychotics
are required to sedate patients. Furthermore,
donep eztl exacerbates positive symptoms in
BPSD and induces epilepsy when the
physical condition of patients is not good. A
low dose of donep eztl such as 1-3 mg is
effective for apathy as well as hallucination
and may function like a placebo. Parkinson's
disease is one of the most placebo-effective
diseases. Memantine is harmful because it
worsens hallucination and delusior, as well
as apathy.
Parkinsonism in NCD with Lewy bodies
is treated with levodops, but the dose should
be as low as possible because levodopa easily
induces hypotension and hallucination in
NCD with Lewy bodies more than in
Parkinson's disease.
3。4.Vascular NCD
According to the lN'ational lnstitute Of
Neurological lDisorders and Stroke‐ AssociatiOn
lnternationale  pour  la  R′echerche  et
l'Enseignement  en Neurosciences criteria,
vascular NCI)is diagnOsed when CVI)causes
NCI).The lmost impOrtant thing is the time
course.  When  cognitive  impair]m.ent  is
apparent within 3 months after a CV]D
episode, or impairment ■uctuates Or shOws
stepwise progression following a recognized
stroke, cognitive impairment is considered to
be caused by C\ID. The volume of infarction
is correlated with the severity of cognitive
impairment. Strategic single-infarct NCD is
caused by cerebral infarction of important
brain regions that are responsible for higher-
order brain functiorr.. The symptoms include
memory disturbance, low motivation, abulia,
delirium, and cognitive impairment.
In DSM-5, vascular NCD is defined as
the onset of MND that is chronologically
related to the onset of C\ID, when C\ID is
proven with neuroimaging tests. MND has
characteristic features of intricate attention
as well as executive function disorder related
to frontal lobe dysfunction. Vascular etiology
may range from a large vessel stroke to
microvascular diseasei the presentation is
therefore very heterogeneous, stemming from
the types of vascular lesions and their extent
and location. The lesions may be focal,
multifocal, or diffuse and occur in various
combinations. The cognitive deficits in these
cases can be attributed to the disruption of
cortical-subcortical circuits. Complex attention,
particularly the speed of information processing
and executive ability, are likely to be
affected.
No drugs are approved for the treatment
of vascular NCD by health insurance,
although many so-called brain metabolic
stimulants or cerebral circulation activators
once were used. Drugs for AD are not
recommended.
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3.5. Other diseases that are clinically
diagrosed as AD
Clinically, argyrophilic grain disease is
diagnosed when MND is mild even though
atrophy of the frontal and temporal lobes is
severe. The z scores of AD and arg:yrophilic
grain disease quantified with the voxel-based
specific regional analysis system for AD are
2.L and 4.L, respectively. Argyrophilic grain
disease is sometimes misdiagnosed as AD.
Among aged people, the prevalence of
argyrophilic grain disease is 5-9%. Not all
patients with argyrophilic grain disease show
MND. Senile NCD of the neurofibrillary
tangle (NFT) type is defined as senile NCD
with many NFTs in the hippocampus and
few senile plaques in the brain. Clinical
features of the disease are severe memory
disturbance and other mild cognitive
disturbances. Both argyrophilic grain disease
and senile NCD of the NFT type are
classified into primary age-related tauopathy.
BPSD is more apparent in both diseases
than in AD. Atrophy of the medial temporal
lobe in argyrophilic grain disease is not
symmetrical, although it is symmetrical in
AD.
half of patients with PSP. The prevalence of
PSP was previously reported to be 5 in
100,000. However, recent reports have shown
that the prevalence is approximately 5-20 in
100,000, due to population aging and the
clinical variance of PSP. Pathological PSP is
subdivided into Richardson syndrome, PSP-
Parkinsonisffi, PSP-pure akinesia with gait
freezthg, PSP-corticobasal syndrome, PSP-
non-fluent aphasia, and PSP-cerebellar
ataxia. Cardinal symptoms of BPSD in PSP
include attention deficit, indifference, and a
lack of concern about personal space.
Features of BPSD in PSP used to be called
subcortical NCD, but the feature is almost
the same as frontotemporal NCD. In addition
to the symptoms mentioned above, patients
with PSP show slowness of thought, amnesia,
apathy, lack of vocabulary, depression, and
perseveratiolf..
CBD is a disease with frontal and
parietal lobe atrophy and basal ganglion
degeneration. Typical clinical symptoms of
CBD are unilateral apraxia and muscle
rigidity. Both PSP and CBD are four-repeat
tauopathies. During the disease, 70% of
patients with CBD show MND.
3.6. PSP and CBD
PSP is the second most frequent disease
that shows Parkinsonism. MND in PSP has
received attention, although psychological
symptoms such as cognitive disorder,
character alteration, emotional disorders, or
memory disturbance are initial symptoms in
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認知症の薬物療法について思うこと
鹿児島純心女子大学大学院   岩  田  真
認知症に対 し4種類の薬物の保険適用が認められているが,それ らは疾患自体を治療 しないし,
進行の抑制もしない。たちが悪いことに,興奮や不眠など介護を難 しくする症状を発現させたり,
痙攣のような生命に関わる有害作用を生じさせたりする。認知症患者は他の疾患も併発 している
場合も多く,そのため多剤服用 しているので,服用薬の種類をそれ以上増やさないためにも抗認
知症薬は服用すべきではない。1980年に脳代謝賦活薬,脳循環改善薬 とい うものがあつた。プラ
セボと同じ効果 しか認められず,再審査後にほとんどすべて市場から消えた。現在の抗認知症薬
の処方状況はデジャヴュに他ならない。
しかし,認知症に伴 う行動心理症状 (BPSD)は患者のQOLや尊厳を損なうので積極的に介入す
べきである。その場合,安易に薬物に頼るべきではない。認知症患者はコミュニケーション障害
があるが,その原因を探索し,それに対 して可能な限 リケアの工夫などで対処すべきである。非
薬物的対応が奏功しない場合は薬物を少量,短期間投与する。長期に渡 らざる得ない場合は中止
可能かどうか定期的にチェックすべきである。
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